Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy

Background Thyroid hormone (TH) is known to enhance arrhythmogenicity, and high-normal thyroid function is related with an increased recurrence of atrial fibrillation (AF) after catheter ablation. However, the impact of thyroid hormone replacement (THR) on AF ablation is not well known. Methods This...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of interventional cardiac electrophysiology 2017-08, Vol.49 (2), p.111-117
Hauptverfasser: Kim, Ki-Hun, Mohanty, Sanghamitra, Mohanty, Prasant, Trivedi, Chintan, Morris, Eli Hamilton, Santangeli, Pasquale, Bai, Rong, Al-Ahmad, Amin, Burkhardt, John David, Gallinghouse, Joseph G., Horton, Rodney, Sanchez, Javier E., Bailey, Shane, Hranitzky, Patrick M., Zagrodzky, Jason, Kim, Soo G., Di Biase, Luigi, Natale, Andrea
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Thyroid hormone (TH) is known to enhance arrhythmogenicity, and high-normal thyroid function is related with an increased recurrence of atrial fibrillation (AF) after catheter ablation. However, the impact of thyroid hormone replacement (THR) on AF ablation is not well known. Methods This study evaluated 1163 consecutive paroxysmal AF patients [160 (14%) on THR and 1003 (86%) without THR] undergoing their first catheter ablation. A total of 146 patients on THR and 146 controls were generated by propensity matching, based on calculated risk factor scores, using a logistic model (age, sex, body mass index, and left atrium size). The presence of non-pulmonary vein (PV) triggers was disclosed by a high-dose isoproterenol challenge (up to 30 μg/min) after PV isolation. Results Clinical characteristics were not different between the groups. When compared to the control, non-PV triggers were significantly greater in the THR patients [112 (77%) vs. 47 (32%), P  
ISSN:1383-875X
1572-8595
DOI:10.1007/s10840-017-0234-x